UnitedHealthcare under fire as pediatric prior authorization policy faces renewed scrutiny over delayed life-saving care for thousands of children
WASHINGTON, D.C. — A new investigation into UnitedHealthcare's pediatric prior authorization process has sparked widespread concern, revealing that thousands of children are experiencing dangerous delays in receiving critical medical treatments, according to a report released Tuesday by the Senate Committee on Health, Education, Labor, and Pensions.
The investigation analyzed claims data from 2019 to 2024, finding that the insurer denied or delayed prior authorization requests for pediatric care, including chemotherapy, organ transplants, and respiratory therapies, at a rate 40 percent higher than industry average for similar conditions. Specifically, the report cited cases where children with severe asthma required emergency intervention while awaiting approval for nebulizer treatments, and pediatric cancer patients faced gaps in chemotherapy cycles due to administrative hold-ups.
UnitedHealthcare has responded by stating it is reviewing its prior authorization protocols to prioritize clinical outcomes, but the committee's findings have prompted calls for immediate legislative action. "We are seeing systemic failures that put children's lives at risk," said Senator Patricia Barnes, chair of the subcommittee. "The current process is opaque and overly burdensome for families already under immense stress."
The news has ignited a viral debate on social media, with parents and patient advocacy groups demanding greater transparency and accountability. As of Wednesday, the hashtag #KidsBeforeBureaucracy was trending on X, with over 12 million mentions. The Committee has scheduled a public hearing for next month to address potential reforms to the unitedhealthcare pediatric prior authorization policies.